Acute on Chronic Liver Failure Market to Surge as Key Companies Such as Grifols Therapeutics, Versantis AG, Promethera Biosciences, and Others are Exploring the Therapeutics Segment, Assesses DelveInsight

DelveInsight's "Acute on Chronic Liver Failure - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Acute on Chronic Liver Failure market share of the individual therapies, current and forecasted Acute on Chronic Liver Failure market size from 2019 to 2032 segmented by seven major markets.

The report also offers current Acute on Chronic Liver Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute on Chronic Liver Failure market.

Key Takeaways from the Acute on Chronic Liver Failure Market Report
According to DelveInsight estimates, the Acute on Chronic Liver Failure market size is expected to grow significantly at a considerable CAGR by 2032.

Both hepatic (alcohol-induced liver injury) and extrahepatic (bacterial infections or gastrointestinal hemorrhage) disorders were the most common precipitating disorders for acutely decompensated cirrhosis, with or without ACLF.

Globally, key Acute on Chronic Liver Failure companies such as Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT, and others are developing novel Acute on Chronic Liver Failure drugs that can be available in the Acute on Chronic Liver Failure market in the upcoming years.

Promising Acute on Chronic Liver Failure therapies in the pipeline include Albutein (PE-A 5%), HepaStem, VS-01, and others.

In November 2022, GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients suffering from liver diseases with significant unmet medical needs, announced the highlights of its Pipeline Day events, which reviewed the Company's clinical progress and recent strategic updates.

In September 2022, In a small-time buyout, Genfit SA agreed to acquire Versantis, a Swiss startup, for CHF40 million upfront.

In June 2022, Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, announced today data demonstrating that both single and repeated intraperitoneal administrations of VS-01 reduced the concentrations of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) associated with ACLF.

Discover more about therapies set to grab major Acute on Chronic Liver Failure market share @ Acute on Chronic Liver Failure Market Report- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute on Chronic Liver Failure Overview
The term 'acute-on-chronic liver failure (ACLF)' refers to a sudden and potentially fatal worsening of clinical conditions in patients with cirrhosis or chronic liver disease. ACLF is a severe condition with a high morbidity and mortality rate. The European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium defines ACLF as the failure of one of the six major organ systems. The CLIF-C Organ Failure scale is used to assess the failure of each organ system.

According to NACSELD, the most common organ system failures were brain (36%), circulatory (16%), kidney (13%), and respiratory (9%). 3 The observed 30-day mortality rate gradually increased from 4% in patients with no OF to 27%, 49%, 64%, and 77% in patients with 1, 2, 3, or 4 OFs, respectively.

Learn more about the Acute on Chronic Liver Failure treatment guidelines @ ACLF Guidelines

Acute on Chronic Liver Failure Epidemiological Insights
According to Delveinsight, grade 1 cases accounted for the maximum number of ACLF cases.

DelveInsight's analysis shows that the cases of ACLF show an increasing trend in the forecasted period (2019-2032) in the United States.

The ACLF market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Prevalence of ACLF
Prevalent cases of ACLF by Grades
Organ failures associated with ACLF
Potential precipitating events of ACLF

Download the report to understand which factors are driving Acute on Chronic Liver Failure epidemiology trends @ Acute on Chronic Liver Failure Epidemiological Insights-https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute on Chronic Liver Failure Treatment Market
There is currently no specific treatment available for ACLF patients. ACLF management includes etiology-based treatment, controlling and treating complications, providing an artificial liver support system, and performing a liver transplant. Patients with ACLF should preferably be admitted to transplant centers. Organ functions must be closely monitored, and organ-specific treatment is required to prevent multiorgan failure.

The main principles of management in these patients are to support each failing organ and promote hepatic gland recovery. The current treatment consists of detoxification devices, antiviral therapy, and liver transplantation.

To know more about Acute on Chronic Liver Failure treatment options, visit @ ACLF Drugs- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute on Chronic Liver Failure Pipeline Therapies
Albutein (PE-A 5%)
HepaStem
VS-01
Acute on Chronic Liver Failure Key Companies
Promethera Biosciences
Akaza Bioscience
RHEACELL
Tianjin Weikai Bioeng., Ltd.
Steminent Biotherapeutics Inc.
Martin Pharmaceuticals, Inc.
GNI Group Ltd.
Versantis
GENFIT

Learn more about the Acute on Chronic Liver Failure therapies in clinical trials @ New Treatment for ACLF- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute on Chronic Liver Failure Market Dynamics
Many medical factors influence the global acute liver failure treatment market. Drug-induced acute liver failure is one of the common factors driving the acute liver treatment market. For example, excessive acetaminophen dosage has been identified as the leading cause of acute liver failure in the United States.

As per DelveInsight analysis, Among the EU-5 countries, Germany accounts for the highest market size of the Acute-on-Chronic Liver Failure (ACLF) Market.

In the last five years, the field of ACLF has moved very quickly to meet the current unmet need. The availability of a large volume of published data from the East and West has allowed the initial definitions to be reassessed. Attempts to prevent, mitigate, or reverse the ongoing injury would allow for the restoration of hepatic synthetic functions and the reversal of liver damage. Early predictors of mortality and irreversibility of the condition would pave the way for such patients to receive priority liver transplantation.

Scope of the Acute on Chronic Liver Failure Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute on Chronic Liver Failure Companies: Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT (EPA: GNFT), and others
Key Acute on Chronic Liver Failure Therapies: Albutein (PE-A 5%), HepaStem, VS-01, and others
Therapeutic Assessment: Acute on Chronic Liver Failure current marketed and emerging therapies
Acute on Chronic Liver Failure Market Dynamics: Acute on Chronic Liver Failure market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute on Chronic Liver Failure Market Access and Reimbursement

Discover more about Acute on Chronic Liver Failure drugs in development @ ACLF Clinical Trials- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents

1. Acute on Chronic Liver Failure Market Key Insights
2. Acute on Chronic Liver Failure Market Report Introduction
3. Acute on Chronic Liver Failure Market Overview at a Glance
4. Acute on Chronic Liver Failure Market Executive Summary
5. Disease Background and Overview
6. Acute on Chronic Liver Failure Treatment and Management
7. Acute on Chronic Liver Failure Epidemiology and Patient Population
8. Patient Journey
9. Acute on Chronic Liver Failure Marketed Drugs
10. Acute on Chronic Liver Failure Emerging Drugs
11. Seven Major Acute on Chronic Liver Failure Market Analysis
12. Acute on Chronic Liver Failure Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Acute on Chronic Liver Failure Market Drivers
16. Acute on Chronic Liver Failure Market Barriers
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Get in touch with our Business executive @ Healthcare Due Diligence Services- https://www.delveinsight.com/consulting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/consulting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.